Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 25 of 162 entries
View as:

A Study to Evaluate the Effects of Phenytoin and Itraconazole on Sonrotoclax (BGB-11417) in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT06543043 Org: User:
Start: 08/19/24 End: 11/07/24 Due: 11/07/25

Study of the Safety and Pharmacokinetics of BGB-283 (Lifirafenib) and PD-0325901 (Mirdametinib) in Participants With Advanced or Refractory Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT03905148 Org: User:
Start: 05/01/19 End: 02/28/26 Due: 02/28/27

Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05577702 Org: User:
Start: 03/15/23 End: 01/23/25 Due: 01/23/26

A Phase 1b Study to Assess Sitravatinib in Combination With Tislelizumab in Participants With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT03666143 Org: User:
Start: 11/01/18 End: 01/05/23 Due: 01/05/24

A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation

Phase: N/A Priority: Normal
NCT ID: NCT04002297 Org: User:
Start: 08/20/19 End: 12/31/27 Due: 12/31/28

An Investigational Study of BG-89894 Tablets in Participants With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT06568614 Org: User:
Start: 10/12/24 End: 12/30/28 Due: 12/30/29

Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Participants With B-cell Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT04170283 Org: User:
Start: 01/21/20 End: 12/31/28 Due: 12/31/29

Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT02343120 Org: User:
Start: 09/04/14 End: 03/31/21 Due: 03/31/22

A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors

Phase: N/A Priority: Normal
NCT ID: NCT06257264 Org: User:
Start: 03/11/24 End: 02/28/28 Due: 02/28/29

A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05609370 Org: User:
Start: 01/29/23 End: 12/31/26 Due: 12/31/27

Treatment of CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibitor Zanubrutinib

Phase: N/A Priority: Normal
NCT ID: NCT05068440 Org: User:
Start: 08/11/21 End: 10/21/25 Due: 10/21/26

A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab, in Participants With Advanced or Metastatic Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT06427941 Org: User:
Start: 07/23/24 End: 10/30/26 Due: 10/30/27

Phase 1 Study to Investigate Effect of Rifampin and Itraconazole on the Pharmacokinetics of BGB-3111 in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT03301181 Org: User:
Start: 09/18/17 End: 11/13/17 Due: 11/13/18

Phase 3 Study of Tislelizumab Versus Sorafenib in Participants With Unresectable HCC

Phase: N/A Priority: Normal
NCT ID: NCT03412773 Org: User:
Start: 12/28/17 End: 12/14/23 Due: 12/14/24

A Study Evaluating the Efficacy and Safety of Tislelizumab Versus Chemotherapy in Advanced Non-Squamous Non-small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03663205 Org: User:
Start: 07/23/18 End: 04/26/23 Due: 04/26/24

A Study of How [14C]-BGB-16673 is Absorbed, Broken Down, and Removed From the Body After a Single Oral Dose in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT06776679 Org: User:
Start: 01/24/25 End: 03/27/25 Due: 03/27/26

Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT03736889 Org: User:
Start: 09/19/18 End: 09/30/27 Due: 09/30/28

Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab

Phase: N/A Priority: Normal
NCT ID: NCT04282018 Org: User:
Start: 05/25/20 End: 08/28/24 Due: 08/28/25

A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Participants With Stage III Unresectable Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04866017 Org: User:
Start: 06/17/21 End: 10/17/23 Due: 10/17/24

To Evaluate the Efficacy and Safety of Tislelizumab in Combination With Lenvatinib in Patients With Selected Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT05014828 Org: User:
Start: 09/18/21 End: 07/09/24 Due: 07/09/25

Safety, Tolerability, and Pharmacokinetics of BGB-23339 in Healthy Japanese and Caucasian Subjects

Phase: N/A Priority: Normal
NCT ID: NCT05387668 Org: User:
Start: 02/17/22 End: 10/17/22 Due: 10/17/23

Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05014815 Org: User:
Start: 11/16/21 End: 09/04/24 Due: 09/04/25

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT06120283 Org: User:
Start: 12/01/23 End: 06/30/28 Due: 06/30/29

Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT04047862 Org: User:
Start: 08/15/19 End: 08/07/24 Due: 08/07/25

A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia

Phase: N/A Priority: Normal
NCT ID: NCT05952037 Org: User:
Start: 09/28/23 End: 08/31/28 Due: 08/31/29